NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Myriad Genetics' BRACAnalysis CDx as a complementary diagnostic to identify ovarian cancer patients with germline BRCA mutations who are likely to benefit most from treatment with Zejula (niraparib).